BCR and B-cell chronic lymphocytic leukemia: The recombinant anti- α4 antibody natalizumab has been studies in the laboratory and shown to reduce migratory ability, interfere with CLL cell recirculation and mobilization of stem and progenitor cells from the bone marrow in vitro, thus having a similar effect to that seen in cells exposed to kinase inhibitors targeting BCR (47).